Taebo Sim

8.9k total citations · 1 hit paper
122 papers, 5.2k citations indexed

About

Taebo Sim is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Taebo Sim has authored 122 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Molecular Biology, 44 papers in Organic Chemistry and 31 papers in Oncology. Recurrent topics in Taebo Sim's work include Melanoma and MAPK Pathways (20 papers), Synthesis and biological activity (18 papers) and Protein Kinase Regulation and GTPase Signaling (15 papers). Taebo Sim is often cited by papers focused on Melanoma and MAPK Pathways (20 papers), Synthesis and biological activity (18 papers) and Protein Kinase Regulation and GTPase Signaling (15 papers). Taebo Sim collaborates with scholars based in South Korea, United States and Egypt. Taebo Sim's co-authors include Nathanael S. Gray, Jianming Zhang, Qingsong Liu, David M. Sabatini, Seong A. Kang, Carson C. Thoreen, Jae Won Chang, Yi Gao, Laurie J. Reichling and Wooyoung Hur and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and SHILAP Revista de lepidopterología.

In The Last Decade

Taebo Sim

119 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

2009 1.4k citations Carson C. Thoreen, Seong A. Kang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Taebo Sim South Korea	31	3.5k	1.1k	951	609	504	122	5.2k
Evripidis Gavathiotis United States	38	4.5k 1.3×	780 0.7×	412 0.4×	485 0.8×	787 1.6×	75	5.8k
A. Chaikuad Germany	37	2.9k 0.8×	784 0.7×	760 0.8×	349 0.6×	213 0.4×	123	4.4k
Tinghu Zhang United States	38	5.3k 1.5×	2.3k 2.2×	792 0.8×	573 0.9×	175 0.3×	81	6.7k
Christine Lukacs United States	21	3.9k 1.1×	2.5k 2.4×	625 0.7×	484 0.8×	328 0.7×	35	5.3k
Maria Ruzzene Italy	41	4.5k 1.3×	1.1k 1.1×	475 0.5×	665 1.1×	187 0.4×	120	6.1k
Markus Wartmann Switzerland	39	3.8k 1.1×	2.1k 2.0×	1.1k 1.2×	948 1.6×	172 0.3×	89	6.9k
Ker Yu United States	36	3.3k 0.9×	631 0.6×	800 0.8×	167 0.3×	338 0.7×	84	4.5k
Uwe Rix United States	38	2.6k 0.7×	1.0k 1.0×	841 0.9×	269 0.4×	117 0.2×	89	4.9k
Henrik Daub Germany	35	5.4k 1.5×	1.7k 1.6×	290 0.3×	1.1k 1.8×	325 0.6×	56	7.6k
Alex N. Bullock United Kingdom	49	6.1k 1.7×	2.8k 2.7×	872 0.9×	603 1.0×	259 0.5×	108	8.7k

Countries citing papers authored by Taebo Sim

Since Specialization

Citations

This map shows the geographic impact of Taebo Sim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taebo Sim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taebo Sim more than expected).

Fields of papers citing papers by Taebo Sim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taebo Sim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taebo Sim. The network helps show where Taebo Sim may publish in the future.

Co-authorship network of co-authors of Taebo Sim

This figure shows the co-authorship network connecting the top 25 collaborators of Taebo Sim. A scholar is included among the top collaborators of Taebo Sim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taebo Sim. Taebo Sim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Goosang, et al.. (2025). Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing. Nature Biomedical Engineering.

Seo, Dong-Hyun, Man Sup Kwak, In Ho Park, et al.. (2025). Apomorphine is a novel necroptosis inhibitor targeting mixed lineage kinase domain-like protein oligomerization. Cell Death Discovery. 11(1). 457–457. 1 indexed citations

Kim, K. W., Ji-Yun Kim, Yoon Dae Han, et al.. (2024). Site-specific mutagenesis screening in KRAS mutant library to uncover resistance mechanisms to KRASG12D inhibitors. Cancer Letters. 591. 216904–216904. 5 indexed citations

Kim, Jungmin, et al.. (2024). Targeted degradation of METTL3 against acute myeloid leukemia and gastric cancer. European Journal of Medicinal Chemistry. 279. 116843–116843. 9 indexed citations

Kim, Younghoon, SeongShick Ryu, Hanna Cho, et al.. (2023). Identification of Pyrido[3,4-d]pyrimidine derivatives as RIPK3-Mediated necroptosis inhibitors. European Journal of Medicinal Chemistry. 259. 115635–115635. 2 indexed citations

Kim, Hyun‐Joo, Ho‐June Lee, Taebo Sim, et al.. (2022). AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis. Cell Death and Disease. 13(5). 469–469. 4 indexed citations

Ryu, SeongShick, Benjamin Fram, Jie Jiang, et al.. (2021). Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9. SHILAP Revista de lepidopterología. 1. 100008–100008. 2 indexed citations

Kim, Younghoon, Sandip Sengupta, & Taebo Sim. (2021). Natural and Synthetic Lactones Possessing Antitumor Activities. International Journal of Molecular Sciences. 22(3). 1052–1052. 19 indexed citations

Shin, Injae, et al.. (2020). The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations. Biochemical and Biophysical Research Communications. 532(2). 315–320. 7 indexed citations

10.

Sengupta, Sandip, Byung Joo Lee, Hanna Cho, et al.. (2019). Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis. Journal of Medicinal Chemistry. 62(20). 9141–9160. 9 indexed citations

11.

Chong, Curtis R., Magda Bahcall, Marzia Capelletti, et al.. (2016). Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clinical Cancer Research. 23(1). 204–213. 67 indexed citations

12.

Bahcall, Magda, Taebo Sim, Cloud P. Paweletz, et al.. (2016). Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discovery. 6(12). 1334–1341. 114 indexed citations

13.

Yoon, Hojong, et al.. (2015). A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants. Journal of Medicinal Chemistry. 59(1). 358–373. 28 indexed citations

14.

Lee, Jiyeon, et al.. (2015). One step synthesis of quantum dot–magnetic nanoparticle heterodimers for dual modal imaging applications. The Analyst. 140(8). 2864–2868. 15 indexed citations

15.

Abdelazem, Ahmed Z., Mohammad M. Al‐Sanea, Kyung Ho Yoo, et al.. (2014). Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors. European Journal of Medicinal Chemistry. 90. 195–208. 13 indexed citations

16.

Lee, Jiyeon, Heeyeon Kim, Taebo Sim, & Rita Song. (2013). A new quantum dot–platinum conjugate for self-assembled nanoconjugates by coordination bonding mediated recognition. Chemical Communications. 49(55). 6182–6182. 5 indexed citations

17.

Kim, Han Jo, Il Hwan Kim, Mohammed I. El‐Gamal, et al.. (2012). New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: Design, synthesis, and antiproliferative activity against melanoma cell line. Bioorganic & Medicinal Chemistry Letters. 22(9). 3269–3273. 29 indexed citations

18.

Kim, Mi‐Hyun, Minjung Kim, Il Hwan Kim, et al.. (2011). Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. Bioorganic & Medicinal Chemistry. 19(6). 1915–1923. 25 indexed citations

19.

Liu, Qingsong, Jae Won Chang, Jinhua Wang, et al.. (2010). Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer. DSpace@MIT (Massachusetts Institute of Technology). 11 indexed citations

20.

Zhang, Guobao, Pingda Ren, Nathanael S. Gray, et al.. (2009). Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. Bioorganic & Medicinal Chemistry Letters. 19(23). 6691–6695. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact